Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Other Accumulated Expenses (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Other Accumulated Expenses for 7 consecutive years, with $1.3 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Other Accumulated Expenses changed N/A year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Mar 2025, changed N/A, and an annual FY2024 reading of $1.3 million, changed N/A over the prior year.
  • Other Accumulated Expenses was $1.3 million for Q1 2025 at VYNE Therapeutics, roughly flat from $1.3 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.3 million in Q2 2024 and bottomed at $104000.0 in Q1 2021.
  • Average Other Accumulated Expenses over 3 years is $794857.1, with a median of $1.3 million recorded in 2024.
  • Peak annual rise in Other Accumulated Expenses hit 126.09% in 2021, while the deepest fall reached 72.77% in 2021.
  • Year by year, Other Accumulated Expenses stood at $104000.0 in 2021, then surged by 1162.5% to $1.3 million in 2024, then changed by 0.0% to $1.3 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for VYNE at $1.3 million in Q1 2025, $1.3 million in Q4 2024, and $1.3 million in Q3 2024.